1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014

Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 49 pages

Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014’, provides an overview of the Vasomotor Symptoms of Menopause’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasomotor Symptoms of Menopause, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasomotor Symptoms of Menopause and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vasomotor Symptoms of Menopause and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vasomotor Symptoms of Menopause products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasomotor Symptoms of Menopause pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasomotor Symptoms of Menopause
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Vasomotor Symptoms of Menopause - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vasomotor Symptoms of Menopause Overview 6
Therapeutics Development 7
Pipeline Products for Vasomotor Symptoms of Menopause - Overview 7
Pipeline Products for Vasomotor Symptoms of Menopause - Comparative Analysis 8
Vasomotor Symptoms of Menopause - Therapeutics under Development by Companies 9
Vasomotor Symptoms of Menopause - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Vasomotor Symptoms of Menopause - Products under Development by Companies 15
Vasomotor Symptoms of Menopause - Companies Involved in Therapeutics Development 16
Pfizer Inc. 16
Arbor Pharmaceuticals, LLC. 17
Pantarhei Bioscience BV 18
EndoCeutics, Inc. 19
Ausio Pharmaceuticals, LLC 20
Edgemont Pharmaceuticals, LLC 21
Vasomotor Symptoms of Menopause - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 31
(bazedoxifene + conjugated estrogens) - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
(prasterone + acolbifene) - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
(estrogen + progesterone) - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AUS-131 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
AR-08 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
FP-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
EDG-007 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Vasomotor Symptoms of Menopause - Recent Pipeline Updates 41
Vasomotor Symptoms of Menopause - Discontinued Products 43
Vasomotor Symptoms of Menopause - Product Development Milestones 44
Featured News and Press Releases 44
Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection 44
Oct 03, 2013: Pfizer Announces FDA Approval Of DUAVEE For The Treatment Of Moderate-To-Severe Vasomotor Symptoms Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis 44
Dec 13, 2012: Pfizer And Ligand Pharma Announce FDA Acceptance Of New Drug Application For Bazedoxifene/Conjugated Estrogens 46
Jul 19, 2012: EMA Accepts Regulatory Submission For Pfizer's Bazedoxifene/Conjugated Estrogens For Treatment Of Symptoms Associated With Menopause And Osteoporosis 46
Dec 01, 2008: FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream 47
Apr 07, 2000: Cenestin Achieves Important First Step in Path Toward Osteoporosis Indication 47
Jul 20, 1999: Cenestin(TM) (Synthetic Conjugated Estrogens, A), a Plant-Derived Alternative To Premarin(R) Now Available for Menopausal Women Seeking Symptom Relief 47
Jun 03, 1999: Duramed Receives Patent for Tablet Composition of Cenestin 47
Mar 24, 1994: Duramed Pharmaceuticals Receives FDA Marketing Approval for Cenestin, the New Plant-Derived Synthetic Conjugated Estrogens 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause, H1 2014 7
Number of Products under Development for Vasomotor Symptoms of Menopause - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Comparative Analysis by Unknown Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Vasomotor Symptoms of Menopause - Pipeline by Pfizer Inc., H1 2014 16
Vasomotor Symptoms of Menopause - Pipeline by Arbor Pharmaceuticals, LLC., H1 2014 17
Vasomotor Symptoms of Menopause - Pipeline by Pantarhei Bioscience BV, H1 2014 18
Vasomotor Symptoms of Menopause - Pipeline by EndoCeutics, Inc., H1 2014 19
Vasomotor Symptoms of Menopause - Pipeline by Ausio Pharmaceuticals, LLC, H1 2014 20
Vasomotor Symptoms of Menopause - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Assessment by Combination Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 30
Vasomotor Symptoms of Menopause Therapeutics - Recent Pipeline Updates, H1 2014 41
Vasomotor Symptoms of Menopause - Discontinued Products, H1 2014 43

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause, H1 2014 7
Number of Products under Development for Vasomotor Symptoms of Menopause - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 22
Assessment by Combination Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.